Skip to content
  • News
  • Contacts
  • Careers
    • Work with us
    • Privacy Notice
  • Investor Relations
  •  
    • Kedrion S.p.A
    • Kedrion Biopharma GmbH
    • Kedrion Biopharma – Austria
    • Kedrion Biopharma – Portugal
    • Kedrion Biopharma – Poland
    • Kedrion Biopharma – Russia
    • HUMAN Bioplazma Kft
    • Kedrion Biopharma Inc.
    • Kedrion Mexicana S.A.
    • KEDPLASMA USA
    • Kedrion Betaphar
  •  
  •  
    • LinkedIn
  • About us
    • Corporate Structure
    • Annual Report
    • Corporate Social Responsibility
      • Code of Conduct
      • Environment, Health & Safety
      • Supporting our people
      • Support to communities
  • Expertise
    • Activities
    • Medical & Scientific Information
    • Research & Development
    • Quality & Safety
  • Therapies
    • Therapeutic areas
      • Rare Diseases
      • Mother and Child Health
      • Intensive care and transplantation
      • Transfusion Medicine
    • Business Partners
  • Services
    • Italian partnership
    • Contract manufacturing
    • Technology transfer
    • Biological Safety Center
  • Donors
    • Plasma
  • Pharmacovigilance
kedrion logo
Find in Kedrion

Therapeutic areas

Our continuing commitment to research, development and innovation aims to meet the therapeutic needs of the largest number of patients living with a rare disease or debilitating condition across the world.

Our Therapeutic Areas include:

  • Rare Diseases
  • Mother and Child Health
  • Intensive care and transplantation
  • Transfusion Medicine

Kedrion

Headquarter: Loc. Ai Conti snc, Castelvecchio Pascoli, 55051-Barga (LU)

Fiscal Code, VAT number and registration number from the Registrar of Companies of Lucca 01779530466

Economic and Administrative Index number CHAMBER OF COMMERCE, INDUSTRY, HANDICRAFT AND AGRICULTURE OF LUCCA 170535
Share Capital fully paid euro 60.453.901,00

HIGHLIGHTS

  • BIOSC for pathogen safety
  • Kedrion Annual Reports

USEFUL INFO

  • Credits
  • Site Map
  • Cookies
  • Terms of Use

Where We Are

© Kedrion 2021 / Kedrion S.p.A

You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.

error: Content is protected !!
Kedrion logo Logo Header Menu
    • About us
      • Corporate Structure
      • Annual Report
      • Corporate Social Responsibility
        • Code of Conduct
        • Environment, Health & Safety
        • Supporting our people
        • Support to communities
    • Expertise
      • Activities
      • Medical & Scientific Information
      • Research & Development
      • Quality & Safety
    • Therapies
      • Therapeutic areas
        • Rare Diseases
        • Mother and Child Health
        • Intensive care and transplantation
        • Transfusion Medicine
      • Business Partners
    • Services
      • Italian partnership
      • Contract manufacturing
      • Technology transfer
      • Biological Safety Center
    • Donors
      • Plasma
    • Pharmacovigilance
  • News
  • Contact
  • Careers
    • Work with us
    • Privacy Notice
  • Investor Relations
  • Kedrion’s Sites
    • Kedrion S.p.A
    • Kedrion Biopharma GmbH
    • Kedrion Biopharma – Austria
    • Kedrion Biopharma – Portugal
    • Kedrion Biopharma – Poland
    • Kedrion Biopharma – Russia
    • HUMAN Bioplazma Kft
    • Kedrion Biopharma Inc.
    • Kedrion Mexicana S.A.
    • KEDPLASMA USA
    • Kedrion Betaphar
  • Social Network
    • LinkedIn